1. Home
  2. AUUD vs ENSC Comparison

AUUD vs ENSC Comparison

Compare AUUD & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Auddia Inc.

AUUD

Auddia Inc.

HOLD

Current Price

$1.06

Market Cap

2.9M

Sector

Technology

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$0.85

Market Cap

3.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AUUD
ENSC
Founded
2012
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
3.1M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
AUUD
ENSC
Price
$1.06
$0.85
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
169.4K
122.1K
Earning Date
03-04-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,487,973.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.51
52 Week Low
$0.82
$0.76
52 Week High
$14.60
$8.25

Technical Indicators

Market Signals
Indicator
AUUD
ENSC
Relative Strength Index (RSI) 51.61 33.75
Support Level $0.95 $0.76
Resistance Level $1.22 $0.95
Average True Range (ATR) 0.10 0.10
MACD 0.01 0.02
Stochastic Oscillator 59.30 26.26

Price Performance

Historical Comparison
AUUD
ENSC

About AUUD Auddia Inc.

Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: